原先不论采用何种药物得以治愈的返流性食管炎患者,大多仍会复发。用H_2受体拮抗剂(H_2-RA)者复发率为40％～50％,用质子泵抑制剂(PPI)者复发率高达80％。高复发率提示抑酸治疗后其基本动力异常仍存在。原先研究提示小剂量硫糖铝不能预防复发。本文旨在通过双盲研究大剂量硫糖铝悬液对食管炎治愈者复发的影响。 方法:184例(>18岁)受试者有明确返流性食管炎病史,试验前Savary-Miller分级Ⅰ～Ⅱ级,经抑酸治疗后内镜证实已治愈,且其后至进入试验间隔≤7天,排除溃疡病、上消化道 Most of the patients with reflux esophagitis who have been cured regardless of the type of drug are still relapse. The recurrence rate was 40% ~ 50% with H_2 receptor antagonist (H_2-RA) and 80% with proton pump inhibitor (PPI). The high recurrence rate suggests that the basic motility abnormalities still exist after acid treatment. The original study suggests that low doses of sucralfate can not prevent recurrence. This article aims to double-blind study of high-dose sucralfate suspension esophagitis cured relapse. Methods: A total of 184 patients (> 18 years old) had a history of reflux esophagitis. Savary-Miller grades Ⅰ ~ Ⅱ before the trial were confirmed by endoscopy after acid suppression treatment, and then entered the test interval ≤ 7 days, excluding ulcer disease, upper gastrointestinal tract